The stock's overall trend over the past six months has been negative, with a decline of 3.43% from the price six months ago. It has significantly underperformed the broader market, as indicated by a negative 6-month relative strength of -0.61. The stock is currently trading at $48.75, which is near the lower end of its 52-week range of $33.07 to $57.55, representing approximately 84.7% of the range's high. Short-term performance has been weak, with the stock down 11.36% over the last three months and 2.17% over the last month, though it has shown relative strength against the S&P 500 in the one-month period. The price has recently rebounded from a low near $46.72 in mid-March to its current level.

Revenue for Q4 2025 was $49.69 billion, showing a year-over-year growth of 5.8% from the same quarter in 2024. Profitability metrics are solid, with a net margin of 15.95% and an operating margin of 19.68% based on trailing data. The company maintains a moderate debt-to-equity ratio of 1.21, indicating a balanced capital structure. Financial health is supported by substantial free cash flow, with a trailing twelve-month figure of $12.61 billion. Operational efficiency is demonstrated by a return on equity (ROE) of 10.06% and a return on assets (ROA) of 0.91%, reflecting effective use of shareholder capital and assets.